INS and type 2 diabetes mellitus: Under pre-T2D conditions (obesity), LNFPIII improved glucose tolerance and insulin sensitivity, by modulating pro-inflammatory responses and by directly inhibiting lipogenesis in hepatocytes, thereby ameliorating hepatic steatosis (112).